Compare Organon & Co. Common Stock (OGN) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs BlackRock TCP Capital Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while BlackRock TCP Capital Corp trades at $4.08 (market cap $335.61M). The key difference: Organon & Co. Common Stock is far larger — about 10.8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (19%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and BlackRock TCP Capital Corp for 89 Days on average.
| OGN | TCPC | |
|---|---|---|
Market Cap | $3.62B | $335.61M |
Volume | 2,892,999 | 435,738 |
Sector | Health | Financials |
52-Week High | $13.81 | $6.20 |
52-Week Low | $5.70 | $3.13 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $11.04B | $1.09B |
Dividend Yield | 0.58% | 19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TCPC trades at $3.98, showing no daily change. The stock exhibits a bullish technical signal, with moving averages supporting an uptrend. Recent Q2 2026 earnings beat expectations at $0.22 per share, and a $523 million portfolio sale has reduced leverage. However, fundamentals show negative revenue and net income trends, with a net loss of $88.93 million in 2025. The company maintains a dividend, with a $0.17 payment scheduled for September 2026.
The outlook is mixed. Positive technicals and strategic portfolio sales provide support, but persistent losses and a class action lawsuit pose significant risks. Analyst sentiment is cautious, with a majority recommending Hold. Investment potential hinges on the success of the strategic review and future profitability improvements amid ongoing financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
